| Released | Contributor | Author | Title | Pages | Price | | 9-Feb-2010 | Plunkett Research, Ltd. | Jack W. Plunkett | Health Care Industry Trends, Statistics & Analysis 2010 (Summary) | 98 |
$199 | | 9-Feb-2010 | Plunkett Research, Ltd. | Jack W. Plunkett | Plunkett's Health Care Technologies Overview 2010 (Summary) | 80 |
$199 | | 9-Feb-2010 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 | | 9-Feb-2010 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 | | 9-Feb-2010 | New Constructs, LLC |
N/A
| REGN: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 | | 9-Feb-2010 | Plunkett Research, Ltd. | Jack W. Plunkett | Health Care Industry Market Research and Competitive Analysis 2010 | 730 |
$299 | | 9-Feb-2010 | EconomicInvestor |
N/A
| "The Economy Matters" Report for REGN: the economy's impact on REGN's price and risk, featuring the powerful EconomicInvestor Star Rating | 6 |
$15 | | 9-Feb-2010 | Pechala's Reports | Lubomir Pechala | REGENERON PHARMACEUTICALS INC (REGN=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 | | 8-Feb-2010 | Stock Traders Daily | Thomas H. Kee Jr. | Trading Report for (REGN). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (REGN). | 5 |
$18 | | 8-Feb-2010 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for REGN | 13 |
$25 |
|
1.52% Nasdaq 
Research Reports
